Sensitivity To Flu Helped OTC Drug Firms End 2017 With Sales Boost
This article was originally published in The Pink Sheet & The Rose Sheet
Cold and flu products performed “extraordinarily strong” wherever an influenza virus hit hardest, demonstrating “how understanding key incidents can really help tactical support and trade strategies at the local level,” market researcher says at CHPA exec conference.
You may also be interested in...
For Successful OTC Switch Proposals, A Good Offense Defends Against Doubters
OTC switch sponsors should identify adversaries early in the application switch process so they can counter arguments that could derail their switch, s consultant advises. Some switches fail because firms target regulatory approval and do little on marketplace performance.
Amazon OTCs Likely A Worry For Retailers, A Remedy For Perrigo
Amazon introduced Basic Care line of cough, cold, allergy and digestive treatment OTCs developed in a partnership with Perrigo. The range could be a major threat to store brand and private label OTCs, though success may depend on whether consumers wait for Amazon deliveries or shop at stores.
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.